<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965389</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-062</org_study_id>
    <secondary_id>2021-000892-35</secondary_id>
    <nct_id>NCT04965389</nct_id>
  </id_info>
  <brief_title>A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants</brief_title>
  <official_title>A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and Oral Solution in Healthy Participants With Additional Food Effect Comparison of a Spray-Dried Dispersion Formulation of Milvexian in Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the absolute oral bioavailability (amount of drug&#xD;
      entering the bloodstream) of spray-dried dispersion (SDD) milvexian capsules in the fed and&#xD;
      fasted states, and to bridge the exposures seen using only the oral solution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute oral bioavailability of milvexian oral solution (fasted)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Derived from plasma concentration vs. time and urinary excretion data. Measured by liquid chromatography/mass spectrometry (LC-MS/MS) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute oral bioavailability of milvexian dose 1 spray-dried dispersion (SDD) (fasted)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Derived from plasma concentration vs. time and urinary excretion data. Measured by liquid chromatography/mass spectrometry (LC-MS/MS) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute oral bioavailability of milvexian dose 1 spray-dried dispersion (SDD) (fed)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Derived from plasma concentration vs. time and urinary excretion data. Measured by liquid chromatography/mass spectrometry (LC-MS/MS) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute oral bioavailability of milvexian dose 2 spray-dried dispersion (SDD) (fasted)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Derived from plasma concentration vs. time and urinary excretion data. Measured by liquid chromatography/mass spectrometry (LC-MS/MS) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute oral bioavailability of milvexian dose 2 spray-dried dispersion (SDD) (fed)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Derived from plasma concentration vs. time and urinary excretion data. Measured by liquid chromatography/mass spectrometry (LC-MS/MS) analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: PR interval</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QRS</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
    <description>The QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QTcF</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QRS axis</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Hematology tests</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Coagulation</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Chemistry tests</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Urinalysis</measure>
    <time_frame>Up to 3 days after the last dose of the drug</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral solution</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <other_name>BMS-986177</other_name>
    <other_name>Milvexian</other_name>
    <other_name>JNJ-70033093</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]BMS-986177 Solution for Infusion</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177 Spray-dried Dispersion Capsules</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, as determined by no clinically significant deviation from normal in medical&#xD;
             history, physical examination, electrocardiograms (ECGs), and clinical laboratory&#xD;
             determinations&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m², inclusive. BMI = weight (kg)/ (height&#xD;
             [m])²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of gastrointestinal (GI) disease, upper or lower GI bleeding within 6 months,&#xD;
             intracranial bleeding, tumor, aneurysms&#xD;
&#xD;
          -  History or evidence of abnormal bleeding or coagulation disorder and/or evidence of&#xD;
             coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent&#xD;
             unexplained bruising or thrombus formation, or a history of spontaneous bleeding, such&#xD;
             as epistaxis, or family history of coagulopathies&#xD;
&#xD;
          -  Any acute or chronic medical illness considered clinically significant by the&#xD;
             investigator&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory, neurological or psychiatric disorder, as judged by the&#xD;
             investigator&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>BMS-986177</keyword>
  <keyword>14C-Microtracer</keyword>
  <keyword>Milvexian</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

